Unknown

Dataset Information

0

Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.


ABSTRACT: Despite aggressive treatment with temozolomide and radiotherapy and extensive research into alternative therapies there has been little improvement in Glioblastoma patient survival. Median survival time remains between 12 and 15 months mainly due to treatment resistance and tumor recurrence. In this study, we aimed to explore the underlying mechanisms behind treatment resistance and the lack of success with anti-EGFR therapy in the clinic. After generating a number of treatment resistant Glioblastoma cell lines we observed that resistant cell lines lacked EGFR activation and expression. Furthermore, cell viability assays showed resistant cells were significantly less sensitive to the anti-EGFR agents when compared to parental cell lines. To further characterise the resistance mechanism in our cells microRNA prediction software identified miR-221 as a negative regulator of EGFR expression. miR-221 was up-regulated in our resistant cell lines, and this up-regulation led to a significant reduction in EGFR expression in both our cultured cell lines and a large cohort of glioblastoma patient tumor tissue.

SUBMITTER: Areeb Z 

PROVIDER: S-EPMC7576591 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.

Areeb Zammam Z   Stuart Sarah F SF   West Alice J AJ   Gomez Juliana J   Nguyen Hong P T HPT   Paradiso Lucia L   Zulkifli Ahmad A   Jones Jordan J   Kaye Andrew H AH   Morokoff Andrew P AP   Luwor Rodney B RB  

Scientific reports 20201020 1


Despite aggressive treatment with temozolomide and radiotherapy and extensive research into alternative therapies there has been little improvement in Glioblastoma patient survival. Median survival time remains between 12 and 15 months mainly due to treatment resistance and tumor recurrence. In this study, we aimed to explore the underlying mechanisms behind treatment resistance and the lack of success with anti-EGFR therapy in the clinic. After generating a number of treatment resistant Gliobla  ...[more]

Similar Datasets

| S-EPMC6491393 | biostudies-literature
| S-EPMC7993499 | biostudies-literature
| S-EPMC6678764 | biostudies-literature
| S-EPMC6237285 | biostudies-literature
| S-EPMC3273683 | biostudies-literature
| S-EPMC10802164 | biostudies-literature
| S-EPMC3637292 | biostudies-other
| S-EPMC9377222 | biostudies-literature
| S-EPMC5346677 | biostudies-literature
| S-EPMC3926825 | biostudies-other